Ryan Bioethicist in Residence | School of Law | SIU

Southern Illinois University



Ryan Bioethicist in Residence

The John and Marsha Ryan Bioethicist in Residence was established in 2006 to fund an annual residence and lecture by a law and/or medicine ethics scholar at the School of Law and School of Medicine at Southern Illinois University.

Each year a leading bioethics scholar will visit classes at the law school and provide a seminar for medical students in Carbondale and Springfield; organize interdisciplinary educational activities for students, residents, and faculty from both institutions; be available to mentor law and medicine students; offer a public lecture on his or her scholarship as it relates to law and medicine; and be invited to submit a written version of this lecture for publication in the Journal of Legal Medicine.

past programs

2016 Ryan Bioethicist

Leigh Turner

Leigh Turner, Ph.D., M.A.

October 18-20, 2016

October 18, 2016 at 5 p.m.
Public lecture in Carbondale

Direct-to-Consumer Marketing of Unproven Stem Cell Interventions: Ethical, Legal, and Scientific Concerns

1.0 hour CLE - To register, email aruiz@siu.edu

Listen to WSIU interview with Dr. Leigh Turner here

October 20, 2016 at 9 a.m.
SIU School of Medicine | South Auditorium | 801 N. Rutledge Street | Springfield, IL

From "Stem Cell Tourism" to U.S. Business Marketing Stem Cell Treatments: Ethical, Legal, and Social Issues Related to Clinics Selling Unproven Stem Cell Interventions

Both Lectures are free and open to the public

Leigh Turner is an Associate Professor at the University of Minnesota Center for Bioethics and School of Public Health. Turner is a co-editor of "Risks and chanllenges in Medical Tourism: Understanding the Global Market for Health Services" and "The View from Here: Bioethics and the Social Services". He is the author of numerous publications examining ethical and social issues related to transnational medical travel and globalization of health care. Turner's current research addresses ethical, legal and regulatory concerns associated with U.S. and international clinics marketing unproven and unlicensed cell-based interventions. In particular, he is investingating the global proliferation of clinics marketing "stem cell treatments" for amyotrophic lateral sclerosis, Parkinson disease, multiple sclerosis and many other diseases.